BioNJ Announces Lineup for BioPartnering Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BRIDGEWATER, N.J., May 02, 2022 Nevakar Injectables Inc. , a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in. | May 2, 2022
Nevakar Announces Formation Of Ophthalmic Company, Vyluma
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ Nevakar Inc. ( Nevakar ), a privately held biopharmaceutical company, today announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases. At inception Vyluma will operate as a wholly owned subsidiary of Nevakar Inc.
Vyluma will focus on first-in-class and best-in-class ophthalmic pharmaceutical therapies, with an emphasis on refractive errors. Currently, there are no pharmaceutical treatment options approved for refractive errors such as childhood myopia, presbyopia, night vision disturbance, and hyperopia. NVK002 is Vyluma s lead product candidate in late Phase III clinical development with readouts anticipated in the fourth quarter of 2022. If approved, it would be the first pharmaceutical therapy to slow the progr
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine .
Nevakar, Inc.January 28, 2021 GMT Potential to receive up to $135 million upon the successful attainment of several key regulatory and sales milestones
BRIDGEWATER, N.J. and CLERMONT-FERRAND, France, Jan. 28, 2021 (GLOBE NEWSWIRE) Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17. It is currently under clinical evaluation in the CHAMP (Childhood Atropine for Myopia Progression) st